Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC. - Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; et al. (Lung cancer (Amsterdam, Netherlands), 2019)